Brain Advance Access originally published online on October 11, 2007
Brain 2007 130(12):3265-3274; doi:10.1093/brain/awm248
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions
1Department of Molecular Neuroscience and Department of Clinical and Experimental Epilepsy, MRC Centre for Neuromuscular Disease, Institute of Neurology, UCL and National Hospital for Neurology, Queen Square, London and 2Department of Neurology, Muscle and Nerve Centre, Queen Elizabeth Hospital, University of Birmingham NHS Trust, Birmingham, UK
Correspondence to: Prof. M. G. Hanna, Consultant Neurologist and Professor in Clinical Neurology, MRC Centre for Neuromuscular Disease, Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK E-mail: m.hanna{at}ion.ucl.ac.uk
Myotonia congenita (MC) is the commonest genetic skeletal muscle ion channelopathy. It is caused by mutations in CLCN1 on chromosome 7q35, which alter the function of the major skeletal muscle voltage-gated chloride channel. Dominant and recessive forms of the disease exist. We have undertaken a clinical, genetic and molecular expression study based upon a large cohort of over 300 UK patients. In an initial cohort of 22 families, we sequenced the DNA of the entire coding region of CLCN1 and identified 11 novel and 11 known mutations allowing us to undertake a detailed genotype–phenotype correlation study. Generalized muscle hypertrophy, transient weakness and depressed tendon reflexes occurred more frequently in recessive than dominant MC. Mild cold exacerbation and significant muscle pain were equally common features in dominant and recessive cases. Dominant MC occurred in eight families. We noted that four newly identified dominant mutations clustered in exon 8, which codes for a highly conserved region of predicted interaction between the CLC-1 monomers. Expressed in Xenopus oocytes these mutations showed clear evidence of a dominant-negative effect. Based upon the analysis of mutations in this initial cohort as well as a review of published CLCN1 mutations, we devised an exon hierarchy analysis strategy for genetic screening. We applied this strategy to a second cohort of 303 UK cases with a suspected diagnosis of MC. In 23 individuals, we found two mutations and in 86 individuals we identified a single mutation. Interestingly, 40 of the cases with a single mutation had dominant exon 8 mutations. In total 48 individuals (from 34 families) in cohort 1 and 2 were found to harbour dominant mutations (37% of mutation positive individuals, 30% of mutation positive families). In total, we have identified 23 new disease causing mutations in MC, confirming the high degree of genetic heterogeneity associated with this disease. The DNA-based strategy we have devised achieved a genetic diagnosis in 36% of individuals referred to our centre. Based on these results, we propose that exon 8 of CLCN1 is a hot-spot for dominant mutations. Our molecular expression studies of the new exon 8 mutations indicate that this region of the chloride channel has an important role in dominant negative interactions between the two chloride channel monomers. Accurate genetic counselling in MC should be based not only upon clinical features and the inheritance pattern but also on molecular genetic analysis and ideally functional expression data.
Key Words: myotonia congenita; channelopathy; chloride channel; CLCN1
Abbreviations: AA, amino acid; ABI, Applied Biosystems; CK, creatine kinase; del, deletion; DM2, myotonic dystrophy type 2; EMG, electromyography; het, heterozygous; hom, homozygous; Intr., intron; MC, Myotonia congenita; Ped, pedigree; po, open probability; SSCP, single-strand conformational polymorphism; WT, wild-type
Received May 30, 2007. Revised August 31, 2007. Accepted September 17, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J Trip, G Drost, H B Ginjaar, F H M Nieman, A J van der Kooi, M de Visser, B G M van Engelen, and C G Faber Redefining the clinical phenotypes of non-dystrophic myotonic syndromes J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 647 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Meola, M G Hanna, and B Fontaine Diagnosis and new treatment in muscle channelopathies J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 360 - 365. [Abstract] [Full Text] [PDF]
|
|